文献速递前列腺癌

MRI时代前列腺癌主动监测失败预测:多中心跨大西洋队列研究

Predicting Active Surveillance Failure for Patients with Prostate Cancer in the Magnetic Resonance Imaging Era: A Multicentre Transatlantic Cohort Study.
PubMed 文献 · Eur Urol Oncol · 2025-07-10

该回顾性多中心队列研究纳入719例MRI定位的前列腺癌主动监测患者,中位随访5.2年,评估当代MRI驱动主动监测的肿瘤学安全性并识别失败高危因素。结果显示5%发生主动监测失败,筛状GG2组织学是最强预测因子(HR 12.7),MRI可见肿瘤及非筛状GG2亦为独立预测因素。

要点

  • MRI驱动主动监测对合适患者安全,包括非筛状GG2且MRI不可见者。
  • 筛状GG2组织学主动监测失败风险显著升高(HR 12.7),应考虑 upfront 治疗。
  • MRI可见肿瘤和非筛状GG2组织学亦增加失败风险。

核心结论

  • 当代MRI驱动主动监测对合适的前列腺癌患者是安全的,包括非筛状GG2肿瘤,尤其是MRI不可见者。
  • 筛状GG2疾病患者主动监测失败风险较高,应考虑 upfront 治疗。

研究设计与样本

  • 回顾性多中心队列研究,纳入来自美国和英国三个中心的719例MRI定位前列腺癌主动监测患者。
  • 中位随访5.2年。

主要发现

  • 629例(87%)疾病稳定;36例(5%)发生主动监测失败,包括8例(1%)转移和0例前列腺癌死亡;54例(8%)疾病进展。
  • 筛状GG2组织学是主动监测失败的最强预测因子(HR 12.7,95%CI 4.8-33.6;p<0.001)。
  • 肿瘤MRI可见性(HR 5.0,95%CI 1.5-16.5;p=0.009)和非筛状GG2组织学(HR 3.4,95%CI 1.6-7.0;p=0.001)亦为显著预测因子。
  • MRI不可见非筛状GG2与所有GG1肿瘤的无事件生存率相当(两个结局调整后p>0.05)。

关键数值与推荐

  • 主动监测失败定义为前列腺癌特异性死亡、转移、进展至GG≥4或治疗后生化复发的复合终点。
  • 疾病进展定义为组织学进展至GG3或进展为局部晚期疾病。

临床怎么用

  • 对于非筛状GG2且MRI不可见的前列腺癌患者,可安全进行主动监测。
  • 筛状GG2患者应评估 upfront 治疗,因其主动监测失败风险显著增高。

局限性

  • 回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Magnetic resonance imaging (MRI)-driven active surveillance (AS) is increasingly used for management of prostate cancer (PC). The aim of our study was to determine the oncological safety of contemporary MRI-driven AS and identify patients at higher risk of AS failure. METHODS: This retrospective cohort study included AS patients with MRI-localised PC from three US and UK centres. The primary outcome was AS failure, which was defined as a composite of PC-specific mortality, metastasis, progression to grade group (GG) ≥4, or post-treatment biochemical recurrence. The secondary outcome was disease progression, defined as histological progression to GG 3 or progression to locally advanced disease. Hazard ratios (HRs) were estimated using multivariable Cox models, and multiplicity-adjusted log-rank tests were applied to compare event-free survival across subgroups. KEY FINDINGS AND LIMITATIONS: The study cohort comprised 719 patients with median follow-up of 5.2 yr. Of these patients, 629 (87%) had stable disease; 36 (5%) experienced AS failure, including eight (1%) cases of metastasis and no PC-related deaths; and 54 (8%) had disease progression. Cribriform GG 2 histology was the strongest predictor of AS failure (HR 12.7, 95% confidence interval [CI] 4.8-33.6; p < 0.001), followed by tumour MRI visibility (HR 5.0, 95% CI 1.5-16.5; p = 0.009) and noncribriform GG 2 histology (HR 3.4, 95% CI 1.6-7.0; p = 0.001). Event-free survival was comparable for MRI-invisible noncribriform GG 2 and all GG 1 tumours (adjusted p > 0.05 for both outcomes). The study is limited by its retrospective design. CONCLUSIONS AND CLINICAL IMPLICATIONS: Contemporary MRI-based AS for PC is safe for suitable patients, including men with noncribriform GG 2 tumours, particularly those that are MRI-invisible. Conversely, patients with cribriform GG 2 disease are at higher risk of AS failure, so consideration of upfront treatment is warranted for this subgroup.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Sushentsev N, Li IG, Xu G, et al. Predicting Active Surveillance Failure for Patients with Prostate Cancer in the Magnetic Resonance Imaging Era: A Multicentre Transatlantic Cohort Study. Eur Urol Oncol. 2025. PMID: 40645823. doi:10.1016/j.euo.2025.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。